EDAP TMS Q3 revenue up 6%, beats estimates

Edap Tms SA

06/11/2025 12:43

Overview

EDAP TMS Q3 2025 revenue beats analyst expectations, driven by HIFU growth

HIFU revenue increased 49% yr/yr, driven by Focal One sales and U.S. procedures

Net loss for Q3 2025 was €5.0 mln, improved from €6.4 mln in Q3 2024

Outlook

Company reiterates 2025 guidance: core HIFU revenue to grow 26%-34% YoY

Non-core business revenue expected to decline 25%-30% YoY in 2025

EDAP secures €36 mln credit facility to expand Focal One platform

Result Drivers

HIFU GROWTH - 49% YoY revenue increase driven by Focal One sales and U.S. procedure volumes

SYSTEM PLACEMENTS - 167% YoY growth in Focal One system placements

PROCEDURE VOLUMES - 15% YoY growth in U.S. Focal One HIFU procedures

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
EUR 13.88 mln
EUR 12.90 mln (3 Analysts)
Q3 Net Income
-EUR 5.01 mln
Q3 Basic EPS
-EUR 0.13
Q3 Gross Profit
EUR 5.97 mln
Q3 Operating Expenses
-EUR 10.90 mln
Q3 Operating Income
-EUR 4.93 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Edap Tms SA is $1.80, about 15.6% below its November 5 closing price of $2.08

Press Release: ID:nGNE8MLmCz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)